{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-022224","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.752466+00:00","generated_at":"2026-05-25T00:43:53.987002+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Rigel Pharmaceuticals appoints Mark J. Frohlich to board of directors","bullets":["Appointed March 6, 2025; joins class of directors with term expiring at 2027 annual meeting.","Will serve on Corporate Governance, Health Care Compliance Oversight and Nominating Committee and Scientific and Clinical Trial Advisory Committee.","Received initial option grant for 12,000 shares; annual retainer $50,000 plus $10,000 per committee.","Board determined Frohlich is independent under SEC and Nasdaq standards; no familial relationships."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-022224","json":"https://secwatch.observer/filing/0001104659-25-022224.json","markdown":"https://secwatch.observer/filing/0001104659-25-022224.md","text":"https://secwatch.observer/filing/0001104659-25-022224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925022224/0001104659-25-022224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925022224/tm258676d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:43:53.987002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4c24cc73c","claim":"Mark J. Frohlich was appointed as Director at RIGEL PHARMACEUTICALS INC.","evidence_excerpt":"On March 6, 2025 (the “Effective Date”), Mark J. Frohlich was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925022224/0001104659-25-022224-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}